Prime Medicine (PRME) Enterprise Value (2021 - 2026)
Prime Medicine posted quarterly Enterprise Value of -$135.5 million for Q1 2026, up 3.45% year-on-year from -$131.0 million in Q1 2025, and up 23.74% on a QoQ basis from -$177.7 million in Q4 2025.
Prime Medicine (PRME) has 6 years of Enterprise Value data on file, last reported at -$135.5 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 3.45% year-over-year to -$135.5 million; the trailing twelve-month figure through Mar 2026 stood at -$135.5 million (up 3.45% YoY), and the FY2025 full-year result was -$177.7 million, up 4.2% from the prior year.
- Enterprise Value for Q1 2026 stood at -$135.5 million, up from -$177.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$48.8 million in Q3 2023 and bottomed at -$286.1 million in Q4 2022.
- The 5-year median for Enterprise Value is -$140.3 million (2025), against an average of -$151.8 million.
- Peak annual rise in Enterprise Value reached 70.04% in 2024, while the deepest fall reached 151.94% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$286.1 million in 2022, then soared by 59.38% to -$116.2 million in 2023, then plunged by 59.6% to -$185.5 million in 2024, then grew by 4.2% to -$177.7 million in 2025, then grew by 23.74% to -$135.5 million in 2026.
- The last three Enterprise Value figures came in at -$135.5 million (Q1 2026), -$177.7 million (Q4 2025), and -$208.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Prime Medicine | 601.24 Mn | 601.24 Mn | - | -135.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -135.50 Mn |
| Dec 31, 2025 | -177.68 Mn |
| Sep 30, 2025 | -208.43 Mn |
| Jun 30, 2025 | -57.21 Mn |
| Mar 31, 2025 | -140.34 Mn |
| Dec 31, 2024 | -185.47 Mn |
| Sep 30, 2024 | -122.89 Mn |
| Jun 30, 2024 | -60.29 Mn |
| Mar 31, 2024 | -204.11 Mn |
| Dec 31, 2023 | -116.21 Mn |
| Sep 30, 2023 | -48.78 Mn |
| Jun 30, 2023 | -201.22 Mn |
| Mar 31, 2023 | -243.39 Mn |
| Dec 31, 2022 | -286.09 Mn |
| Sep 30, 2022 | -137.12 Mn |
| Jun 30, 2022 | -92.24 Mn |
| Mar 31, 2022 | -164.25 Mn |
| Dec 31, 2021 | -117.74 Mn |
| Sep 30, 2021 | -200.66 Mn |